Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2013

01-04-2013 | Original Article

Diffusion-weighted imaging (b value = 1500 s/mm2) is useful to decrease false-positive breast cancer cases due to fibrocystic changes

Authors: Miho Ochi, Toshiro Kuroiwa, Shunya Sunami, Junji Murakami, Shinichiro Miyahara, Takashi Nagaie, Masafumi Oya, Hidetake Yabuuchi, Masamitsu Hatakenaka

Published in: Breast Cancer | Issue 2/2013

Login to get access

Abstract

Background

We aimed to evaluate the application of apparent diffusion coefficient (ADC) values calculated from diffusion-weighted imaging (DWI) (b value = 1500 s/mm2) in the breast imaging reporting and data system (BI-RADS).

Methods

For 104 cases of breast lesions with definitive histology diagnosis (45 benign cases, 59 malignant cases) in which breast magnetic resonance imaging was performed, ADC values were compared between benign and malignant cases, between ductal carcinoma in situ (DCIS) and fibrocystic changes, and between DCIS and ductal hyperplasia (one type of fibrocystic change). Diagnostic accuracy was compared for a total of 101 images and for 34 images including only nine DCIS and 25 fibrocystic changes between BI-RADS alone (with categories 4a, 4b, and 5 defined as malignancies) and BI-RADS plus ADC.

Results

There were significant differences in mean ADC values between malignant and benign cases (p < 0.0001) and between DCIS and fibrocystic changes (p < 0.002), but not between DCIS and ductal hyperplasia. Positive predictive values were significantly greater for BI-RADS plus ADC than for BI-RADS alone in all cases (70.5% for BI-RADS alone, 81.3% for BI-RADS plus ADC) and in cases of DCIS versus fibrocystic changes (40.9% for BI-RADS alone, 64.3% for BI-RADS plus ADC), resulting in a significant improvement in diagnostic accuracy with the addition of ADC.

Conclusion

Adding ADC values calculated from DWI (b value = 1500 s/mm2) to BI-RADS is a useful way to improve differential diagnostic accuracy for malignant tumors and benign lesions, especially for DCIS versus fibrocystic changes, except in cases of ductal hyperplasia.
Literature
1.
American College of Radiology. Breast imaging reporting and data system (BI-RADS). 4th ed. Reston: American College of Radiology; 2003.
2.
Nakashima K, Sugahara T, Ito K, Nakamura S, Baba Y, Saito R. Usefulness of diffusion-weighted imaging in characterizing breast lesions. Jpn J Magn Reson Med. 2008;28(2):154–61.
3.
Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Hatakenaka M, Sakai S, et al. Differential diagnosis capability between benign and malignant breast tumors by the combination of dynamic contrast-enhanced MRI and diffusion-weighted imaging: assessment with ROC analysis. Med Imaging Inf. 2007;39(10):930–5.
4.
Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy? Am J Roentgenol. 2009;193:840–9.CrossRef
5.
Woodhams R, Marsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci. 2005;4(1):35–42.PubMedCrossRef
6.
Partridge SC, De Martini WB, Kurland BF, Eby PR, White SW, Lehman CD. Quantitative diffusion weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. Am J Roentgenol. 2009;193:1716–24.CrossRef
7.
Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging. 2008;28(5):1157–65.PubMedCrossRef
8.
Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Okafuji T, Soeda H, et al. Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. Eur J Radiol. 2010;75(1):126–32.CrossRef
9.
Kuroki Y, Nasu K, Kuroki S, Sekiguchi R. Application of diffusion-weighted imaging to MR mammography: basics. Jpn Dtsch Med Beriche. 2008;53(2):292–6.
10.
Nakajima M, Nitori T, Matsuda M, Fukushima H, Iihara K, Seki Tl. Clinical application of MRI echoplanar diffusion-weighted imaging (EPI-DWI) for breast cancer diagnosis. Jpn J Med Imaging. 2008;27:9–21.
11.
van den Bosch MA, Daniel BL, Mariano MN, Nowels KN, Biedwell RL, Fong KJ, et al. Magnetic resonance imaging characteristics fibrocystic change of the breast. Invest Radiol. 2005;40(7):436–41.PubMedCrossRef
12.
Chen J-H, Nalcioglu O, Su M-Y. Fibrocystic change of the breast presenting as a focal lesion mimicking breast cancer in MR imaging. J Magn Reson Imaging. 2008;28(6):1499–505.PubMedCrossRef
13.
Nagasawa K, Takahashi K, Inaoka T, Yamada A, Hiranuma H, Sakuma A, et al. Investigation of the application of diffusion-weighted imaging with high b-value in breast cancer. Med Imaging Inf. 2007;39(10):940–3.
14.
Tsuchiya S, Akiyama F, Moritani T. Color atlas of pathology in mammary gland. Tokyo: Bunkodo; 2008.
15.
Mann RM, Kuhl CK, Kinkel K, Boestes C. Breast MRI: guideline from the European Society of Breast Imaging. Eur Radiol. 2008;18:1307–18.PubMedCrossRef
Metadata
Title
Diffusion-weighted imaging (b value = 1500 s/mm2) is useful to decrease false-positive breast cancer cases due to fibrocystic changes
Authors
Miho Ochi
Toshiro Kuroiwa
Shunya Sunami
Junji Murakami
Shinichiro Miyahara
Takashi Nagaie
Masafumi Oya
Hidetake Yabuuchi
Masamitsu Hatakenaka
Publication date
01-04-2013
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-011-0319-9

Other articles of this Issue 2/2013

Breast Cancer 2/2013 Go to the issue

Conference Paper

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

Review Article

The current status of positron emission mammography in breast cancer diagnosis

Original Article

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Case Report

Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases

Original Article

Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)

Original Article

Power Doppler breast ultrasound: association of vascularization and ER/c-erbB-2 co-expression in invasive breast carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits